- Home
- ANIX vs ALDX Comparison
ANIX vs ALDX Comparison
Compare ANIX & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | ALDX |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 95.7M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANIX | ALDX |
|---|---|---|
| Price | $2.83 | $1.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $8.67 | $5.50 |
| AVG Volume (30 Days) | 103.6K | ★ 4.3M |
| Earning Date | 05-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.82 | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $1.07 |
| 52 Week High | $5.46 | $6.18 |
Technical Indicators
Market Signals| Indicator | ANIX | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 35.34 |
| Support Level | $2.74 | $1.48 |
| Resistance Level | $3.10 | $2.33 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | 0.04 | 0.14 |
| Stochastic Oscillator | 80.61 | 78.05 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.